INTRANASAL CRH CHALLENGE

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 促肾上腺皮质激素释放激素存在于身体和大脑中。它是一种应激激素，在应对压力事件时释放。我们认为它可能在抑郁症等疾病中发挥作用，因此可能值得研究，以便开发未来抑郁症和其他精神疾病的治疗方法。在本研究中使用的促肾上腺皮质激素释放因子的形式是肾上腺皮质素。 Corticorelin是在实验室中制成的，类似于绵羊中的促肾上腺皮质激素释放因子。 它是FDA批准用于测试如何以及垂体和肾上腺在体内的工作，通常是通过静脉注射线，或IV。在这项研究中，我们没有使用它来测试你的垂体或肾上腺，而不是给它IV，我们是以鼻腔喷雾器的形式给药。因此，其在本研究中的使用被认为是实验性的。我们预计，您的身体鼻内吸收的药物量远低于静脉注射药物时的吸收量。这将降低药物的风险。 20名健康志愿者和20名有抑郁症病史的非抑郁症受试者将在两个非连续研究日接受鼻内CRH双盲、安慰剂交叉激发。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Corticotropin releasing hormone is present in the body and brain. It is a stress hormone that is released in response to a stressful event. We think that it may play a role in disorders such as depression, and thus may be worth studying in order to develop future treatments of depression and other psychiatric disorders. The form of corticotropin releasing factor being used in this study is corticorelin. Corticorelin is made in a laboratory to be similar to the type of corticotropin releasing factor in sheep. It is FDA approved for testing how well the pituitary and adrenal glands work in the body, and is usually given through an intravenous line, or IV. In this study, we are not using it to test your pituitary or adrenal glands, and instead of giving it IV, we are giving in the form of a nasal sprayer. Therefore its use in this research study is considered experimental. We expect that the amount of drug your body absorbs intranasally to be much less than when the drug is given IV. This should decrease the risks of the drug. 20 healthy volunteers and 20 non-depressed subjects with a history of depression will undergo a double-blind, placebo-crossover challenge with intranasal CRH on two non-consecutive study days.